The STAR™ Tumor Ablation Registry

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02419703

Enrollment

Registered

2015-04-17

Start date

2015-10-31

Completion date

2017-03-20

Last updated

2017-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Lesions in Vertebral Bodies

Brief summary

Registry collecting data on use of The STAR™ Tumor Ablation System.

Detailed description

The STAR Prospective Registry is an observational registry to gather clinical safety and outcome data in patients with painful spinal metastases in the thoracolumbar spine (T1-L5) following targeted radiofrequency ablation (t-RFA) treatment with the STAR™ Tumor Ablation System.

Interventions

DEVICESTAR™ Tumor Ablation System

Targeted Radiofrequency ablation of painful metastatic tumor in the vertebral body.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

22 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subjects with painful spinal metastatic lesions in thoracolumbar vertebrae (T1-L5) that will be treated with t-RFA using the STAR™ Tumor Ablation System. * Have signed informed consent

Exclusion criteria

* Subjects under 18 years old * Subjects with heart pacemakers, or other electronic device implants * Subjects intended for t-RFA in vertebral body levels C1-7

Design outcomes

Primary

Measure	Time frame	Description
Pain relief (Numerical Rating Pain Scale), post t-RFA	1 month	measured by Numerical Rating Pain Scale (NRPS, 0-10 scale)

Secondary

Measure	Time frame	Description
Pain & Quality of Life Improvement (measured by the FACT G7 & Numerical Rating Pain Scale)	1 week, 1 month, 3 month, 6 month, 12 month	measured by the FACT G7 & Numerical Rating Pain Scale

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026